This case study details the poor performance status of a patient with non-small cell lung cancer and cancer anorexia–cachexia syndrome got through the hardest days of high tumor burden and malnutrition, by using a combined therapy of lung cancer-targeted therapy drug and parenteral nutrition. The related literatures were reviewed.
LilenbaumRCCashyJHensingTAYoungSCellaD. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3(2):125–129.
2.
InoueAKobayashiKUsuiK. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27(9):1394–1400.
3.
PaesmansMSculierJPLibertP. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol.1995;13(5):1221–1230.
4.
RadzikowskaEGlazPRoszkowskiK. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol.2002;13(7):1087–1093.
LavianoAMeguidMMInuiA. Therapy insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2(3):158–165.
7.
MantovaniGMacciòAMadedduC. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15(2):200–211.
8.
FearonKStrasserFAnkerSD. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
9.
FearonKC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365(6):565–567.
10.
InuiA. Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52(2):72–91.
11.
LarribaJLPaz-AresLBoverI. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
12.
CataldoVDGibbonsDLPérez-SolerR. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947–955.
13.
ZhouCWuYLChenG. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol.2011;12(8):735–742.
14.
GeelsPEisenhauerEBezjakA. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol. 2000;18(12):2395–2405.
15.
BarberMDRossJAFearonKC. Cancer cachexia. Surg Oncol. 1999;8(3):133–141.
16.
SlavieroKAReadJAClarkeSJRivoryLP. Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer. 2003;46(2):148–157.
17.
HottaKKiuraKTakigawaN. Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer. 2010;70(3):308–312.
18.
LiuSWangDChenBWangYZhaoWWuJ. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer. 2011;73(2):203–210.
19.
LangerCJ.Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?Clin Lung Cancer. 2011;12(5):272–279.
20.
XuXHSuJFuXY. Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011;67(2):475–479.
21.
DySM. Enteral and parenteral nutrition in terminally ill cancer patients: a review of the literature. Am J Hosp Palliat Care. 2006;23(5):369–377.
22.
BurnetteBJatoiA. Parenteral nutrition in patients with cancer: recent guidelines and a need for further study. Curr Opin Support Palliat Care. 2010;4(4):272–275.
23.
BossolaMPacelliFRosaFTortorelliADogliettoGB. Does nutrition support stimulate tumor growth in humans?Nutr Clin Pract. 2011;26(2):174–180.
24.
MitchellJJatoiA. Parenteral nutrition in patients with advanced cancer: merging perspectives from the patient and healthcare provider. Semin Oncol. 2011;38(3):439–442.
